{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:24:39Z","timestamp":1791915879607,"version":"4.3.4"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s13555-025-01457-4","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T13:59:05Z","timestamp":1750427945000},"page":"1985-1998","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Management of Hidradenitis Suppurativa in Special Populations: A Narrative Review"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9876-2629","authenticated-orcid":false,"given":"Teja","family":"Mallela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Passannante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiral","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Onyeji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"1457_CR1","unstructured":"Moltrasio C, et\u00a0al. Polygenic score: a tool for evaluating the genetic background of sporadic hidradenitis suppurativa. J Investig Dermatol. 2024."},{"issue":"5","key":"1457_CR2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/1744666X.2023.2298356","volume":"20","author":"CA Maronese","year":"2024","unstructured":"Maronese CA, et\u00a0al. Biologics for hidradenitis suppurativa: evolution of the treatment paradigm. Expert Rev Clin Immunol. 2024;20(5):525\u201345.","journal-title":"Expert Rev Clin Immunol"},{"issue":"7","key":"1457_CR3","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00403-024-03171-1","volume":"316","author":"S Alnaif","year":"2024","unstructured":"Alnaif S, et\u00a0al. Association between viral control and severity of hidradenitis suppurativa in a cohort of patients with comorbid human immunodeficiency virus and hidradenitis suppurativa. Arch Dermatol Res. 2024;316(7):423.","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"1457_CR4","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1111\/bjd.20591","volume":"185","author":"H Bui","year":"2021","unstructured":"Bui H, et\u00a0al. Hidradenitis suppurativa among patients with HIV: investigating patient and disease characteristics and misdiagnosis. Br J Dermatol. 2021;185(5):1070\u20132.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1457_CR5","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/bjd.18433","volume":"182","author":"PH Deng","year":"2020","unstructured":"Deng PH, Wang CJ, Armstrong AW. An association between hidradenitis suppurativa and HIV. Br J Dermatol. 2020;182(2):490\u20131.","journal-title":"Br J Dermatol"},{"issue":"16","key":"1457_CR6","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1097\/QAD.0000000000001998","volume":"32","author":"A Molina-Leyva","year":"2018","unstructured":"Molina-Leyva A, Badiola J. Severe refractory hidradenitis suppurativa successfully treated with adalimumab in an HIV-positive\/hepatitis C virus-positive patient. AIDS. 2018;32(16):2436\u20138.","journal-title":"AIDS"},{"issue":"12","key":"1457_CR7","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1001\/archdermatol.2010.372","volume":"146","author":"D Alecsandru","year":"2010","unstructured":"Alecsandru D, et\u00a0al. Severe refractory hidradenitis suppurativa in an HIV-positive patient successfully treated with infliximab. Arch Dermatol. 2010;146(12):1343\u20135.","journal-title":"Arch Dermatol"},{"issue":"3","key":"1457_CR8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4103\/0022-3859.101403","volume":"58","author":"G Prabhu","year":"2012","unstructured":"Prabhu G, et\u00a0al. Hidradenitis suppurativa in a HIV-infected child. J Postgrad Med. 2012;58(3):207\u20139.","journal-title":"J Postgrad Med"},{"issue":"1","key":"1457_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0039-6109(05)70536-3","volume":"77","author":"R Gilliland","year":"1997","unstructured":"Gilliland R, Wexner SD. Complicated anorectal sepsis. Surg Clin N Am. 1997;77(1):115\u201353.","journal-title":"Surg Clin N Am"},{"issue":"9","key":"1457_CR10","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1089\/apc.2011.0158","volume":"25","author":"H Husein-ElAhmed","year":"2011","unstructured":"Husein-ElAhmed H, Fernandez-Pugnaire MA, Ruiz-Carrascosa JC. Severe hidradenitis suppurative in an HIV-positive male: use of multiple treatment modalities, including tumor necrosis factor blockade. AIDS Patient Care STDS. 2011;25(9):507\u20138.","journal-title":"AIDS Patient Care STDS"},{"issue":"2","key":"1457_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/bjd\/ljae330","volume":"192","author":"RL Imhof","year":"2025","unstructured":"Imhof RL, et\u00a0al. Management and outcomes of hidradenitis suppurativa in solid organ transplant recipients. Br J Dermatol. 2025;192(2):347\u20139.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1457_CR12","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/iwj.12671","volume":"14","author":"N Jourabchi","year":"2017","unstructured":"Jourabchi N, et\u00a0al. Squamous cell carcinoma complicating a chronic lesion of hidradenitis suppurativa: a case report and review of the literature. Int Wound J. 2017;14(2):435\u20138.","journal-title":"Int Wound J"},{"issue":"2","key":"1457_CR13","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1177\/1203475416668161","volume":"21","author":"B Sotoodian","year":"2017","unstructured":"Sotoodian B, Abbas M, Brassard A. Hidradenitis suppurativa and the association with hematological malignancies. J Cutan Med Surg. 2017;21(2):158\u201361.","journal-title":"J Cutan Med Surg"},{"issue":"1","key":"1457_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.det.2015.08.002","volume":"34","author":"IM Miller","year":"2016","unstructured":"Miller IM, McAndrew RJ, Hamzavi I. Prevalence, risk factors, and comorbidities of hidradenitis suppurativa. Dermatol Clin. 2016;34(1):7\u201316.","journal-title":"Dermatol Clin"},{"key":"1457_CR15","doi-asserted-by":"crossref","unstructured":"Scheinfeld N. A case of a patient with stage III familial hidradenitis suppurativa treated with 3 courses of infliximab and died of metastatic squamous cell carcinoma. Dermatol Online J. 2014;20(3).","DOI":"10.5070\/D3203021764"},{"issue":"2","key":"1457_CR16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/BCR.0000000000000399","volume":"38","author":"JR Yon","year":"2017","unstructured":"Yon JR, et\u00a0al. Marjolin\u2019s ulcer in chronic hidradenitis suppurativa: a rare complication of an often neglected disease. J Burn Care Res. 2017;38(2):121\u20134.","journal-title":"J Burn Care Res"},{"issue":"5","key":"1457_CR17","first-page":"417","volume":"12","author":"S Herschel","year":"2014","unstructured":"Herschel S, Laske J, Stein A. Squamous cell carcinoma arising in hidradenitis suppurativa. J Dtsch Dermatol Ges. 2014;12(5):417\u20139.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"3","key":"1457_CR18","doi-asserted-by":"publisher","first-page":"e316","DOI":"10.1111\/jdv.18598","volume":"37","author":"FR Blum","year":"2023","unstructured":"Blum FR, et\u00a0al. Characterizing the immune checkpoint marker profiles of cutaneous squamous cell carcinomas in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2023;37(3):e316\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1457_CR19","first-page":"427","volume":"14","author":"A Thiem","year":"2016","unstructured":"Thiem A, et\u00a0al. Acne inversa-like skin lesions as a potential adverse event during vemurafenib therapy. J Dtsch Dermatol Ges. 2016;14(4):427\u20138.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"1","key":"1457_CR20","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1111\/ijd.13006","volume":"55","author":"A Verdelli","year":"2016","unstructured":"Verdelli A, et\u00a0al. A fatal case of hidradenitis suppurativa associated with sepsis and squamous cell carcinoma. Int J Dermatol. 2016;55(1):e52\u20133.","journal-title":"Int J Dermatol"},{"issue":"4","key":"1457_CR21","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3109\/09546634.2011.652064","volume":"23","author":"F Kamangar","year":"2012","unstructured":"Kamangar F, Neuhaus IM, Koo JY. An evidence-based review of skin cancer rates on biologic therapies. J Dermatol Treat. 2012;23(4):305\u201315.","journal-title":"J Dermatol Treat"},{"key":"1457_CR22","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2147\/CCID.S512373","volume":"18","author":"F Martora","year":"2025","unstructured":"Martora F, et\u00a0al. Hidradenitis suppurativa cancer risk: a review of the literature. Clin Cosmet Investig Dermatol. 2025;18:617\u201326.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"2","key":"1457_CR23","doi-asserted-by":"publisher","first-page":"192","DOI":"10.4318\/tjg.2012.0340","volume":"23","author":"S Bell\u0131","year":"2012","unstructured":"Bell\u0131 S, et\u00a0al. Squamous cell carcinomas on the basis of chronic inflammatory perianal lesions. Turk J Gastroenterol. 2012;23(2):192\u20133.","journal-title":"Turk J Gastroenterol"},{"issue":"12","key":"1457_CR24","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1136\/annrheumdis-2014-205745","volume":"74","author":"P Raaschou","year":"2015","unstructured":"Raaschou P, Frisell T, Askling J. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis. 2015;74(12):2137\u201343.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1457_CR25","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/MCG.0000000000000865","volume":"53","author":"D Micic","year":"2019","unstructured":"Micic D, et\u00a0al. Risk of cancer recurrence among individuals exposed to antitumor necrosis factor therapy: a systematic review and meta-analysis of observational studies. J Clin Gastroenterol. 2019;53(1):e1\u201311.","journal-title":"J Clin Gastroenterol"},{"issue":"3","key":"1457_CR26","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S2468-1253(19)30362-0","volume":"5","author":"AK Waljee","year":"2020","unstructured":"Waljee AK, et\u00a0al. Anti-tumour necrosis factor-\u03b1 therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study. Lancet Gastroenterol Hepatol. 2020;5(3):276\u201384.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"1457_CR27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.cgh.2015.04.173","volume":"14","author":"S Yadav","year":"2016","unstructured":"Yadav S, et\u00a0al. Hidradenitis suppurativa in patients with inflammatory bowel disease: a population-based cohort study in Olmsted County, Minnesota. Clin Gastroenterol Hepatol. 2016;14(1):65\u201370.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"1457_CR28","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.cgh.2015.09.033","volume":"14","author":"H Eppinga","year":"2016","unstructured":"Eppinga H, Thio HB, van der Woude CJ. Characteristics of patients with hidradenitis suppurativa and inflammatory bowel disease. Clin Gastroenterol Hepatol. 2016;14(3):482\u20133.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"1457_CR29","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/MIB.0000000000000579","volume":"22","author":"IC Janse","year":"2016","unstructured":"Janse IC, et\u00a0al. Identification of clinical and genetic parameters associated with hidradenitis suppurativa in inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(1):106\u201313.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"1457_CR30","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.cgh.2015.04.180","volume":"14","author":"N Kamal","year":"2016","unstructured":"Kamal N, et\u00a0al. Features of patients with Crohn\u2019s disease and hidradenitis suppurativa. Clin Gastroenterol Hepatol. 2016;14(1):71\u20139.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"1457_CR31","first-page":"291","volume":"22","author":"D Diamantova","year":"2014","unstructured":"Diamantova D, Lomickova I, Cetkovska P. Adalimumab treatment for hidradenitis suppurativa associated with Crohn\u2019s disease. Acta Dermatovenerol Croat. 2014;22(4):291\u20133.","journal-title":"Acta Dermatovenerol Croat"},{"issue":"8","key":"1457_CR32","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s00384-014-2110-9","volume":"30","author":"B Murphy","year":"2015","unstructured":"Murphy B, Morrison G, Podmore P. Successful use of adalimumab to treat pyoderma gangrenosum, acne and suppurative hidradenitis (PASH syndrome) following colectomy in ulcerative colitis. Int J Colorectal Dis. 2015;30(8):1139\u201340.","journal-title":"Int J Colorectal Dis"},{"issue":"4","key":"1457_CR33","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.crohns.2010.02.007","volume":"4","author":"M Mortimore","year":"2010","unstructured":"Mortimore M, Florin TH. A role for B\u2081\u2082 in inflammatory bowel disease patients with suppurative dermatoses? An experience with high dose vitamin B\u2081\u2082 therapy. J Crohns Colitis. 2010;4(4):466\u201370.","journal-title":"J Crohns Colitis"},{"issue":"10443","key":"1457_CR34","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","volume":"403","author":"AB Kimball","year":"2024","unstructured":"Kimball AB, et\u00a0al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet. 2024;403(10443):2504\u201319.","journal-title":"Lancet"},{"issue":"6","key":"1457_CR35","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1093\/bjd\/ljae098","volume":"190","author":"CC Zouboulis","year":"2024","unstructured":"Zouboulis CC, et\u00a0al. Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials. Br J Dermatol. 2024;190(6):836\u201345.","journal-title":"Br J Dermatol"},{"key":"1457_CR36","doi-asserted-by":"publisher","first-page":"1124628","DOI":"10.3389\/fphar.2023.1124628","volume":"14","author":"Z Deng","year":"2023","unstructured":"Deng Z, et\u00a0al. IL-17 inhibitor-associated inflammatory bowel disease: a study based on literature and database analysis. Front Pharmacol. 2023;14:1124628.","journal-title":"Front Pharmacol"},{"issue":"11","key":"1457_CR37","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/jama.2024.12414","volume":"332","author":"E Louis","year":"2024","unstructured":"Louis E, et\u00a0al. Risankizumab for ulcerative colitis: two randomized clinical trials. JAMA. 2024;332(11):881\u201397.","journal-title":"JAMA"},{"issue":"10472","key":"1457_CR38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0140-6736(24)01927-5","volume":"405","author":"DT Rubin","year":"2025","unstructured":"Rubin DT, et\u00a0al. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies. Lancet. 2025;405(10472):33\u201349.","journal-title":"Lancet"},{"issue":"10","key":"1457_CR39","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1111\/jdv.19252","volume":"37","author":"AB Kimball","year":"2023","unstructured":"Kimball AB, et\u00a0al. Guselkumab for the treatment of patients with moderate-to-severe hidradenitis suppurativa: a phase 2 randomized study. J Eur Acad Dermatol Venereol. 2023;37(10):2098\u2013108.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1457_CR40","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s13555-023-00913-3","volume":"13","author":"AB Kimball","year":"2023","unstructured":"Kimball AB, et\u00a0al. Efficacy and safety of risankizumab for the treatment of hidradenitis suppurativa: a phase 2, randomized, placebo-controlled trial. Dermatol Ther (Heidelb). 2023;13(5):1099\u2013111.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1457_CR41","unstructured":"Upadacitinib safety and time to relapse: analysis of phase 3 maintenance studies, U-ACHIEVE and U-ENDURE, in patients with moderately to severely active ulcerative colitis. Gastroenterol Hepatol (N Y). 2023;19(12 Suppl 9):7\u20138."},{"key":"1457_CR42","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.jaad.2024.12.046","volume":"92","author":"LS Ackerman","year":"2025","unstructured":"Ackerman LS, et\u00a0al. Improvements in moderate-to-severe hidradenitis suppurativa with upadacitinib: results from a phase 2, randomized, placebo-controlled study. J Am Acad Dermatol. 2025;92:1252.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1457_CR43","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.jaad.2023.10.034","volume":"90","author":"JS Kirby","year":"2024","unstructured":"Kirby JS, et\u00a0al. Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study. J Am Acad Dermatol. 2024;90(3):521\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1457_CR44","doi-asserted-by":"publisher","first-page":"974","DOI":"10.9738\/INTSURG-D-14-00237.1","volume":"100","author":"Y Tokunaga","year":"2015","unstructured":"Tokunaga Y, Sasaki H. Clinical role of modified seton procedure and coring out for treatment of complex anal fistulas associated with hidradenitis suppurativa. Int Surg. 2015;100(6):974\u20138.","journal-title":"Int Surg"},{"issue":"1","key":"1457_CR45","first-page":"61","volume":"86","author":"G Pellino","year":"2015","unstructured":"Pellino G, et\u00a0al. A modified pathway of perineal packing in patients requiring surgery for perineal fistulas with extensive perineal involvement. Ann Ital Chir. 2015;86(1):61\u20135.","journal-title":"Ann Ital Chir"},{"issue":"3","key":"1457_CR46","doi-asserted-by":"publisher","first-page":"164","DOI":"10.2310\/7750.2008.08008","volume":"13","author":"O Bleiziffer","year":"2009","unstructured":"Bleiziffer O, et\u00a0al. Solving acne inversa (hidradenitis suppurativa) in Crohn disease with buried chip skin grafts. J Cutan Med Surg. 2009;13(3):164\u20138.","journal-title":"J Cutan Med Surg"},{"key":"1457_CR47","doi-asserted-by":"publisher","first-page":"838","DOI":"10.5604\/17322693.1019537","volume":"66","author":"M Ko\u0142odziejczak","year":"2012","unstructured":"Ko\u0142odziejczak M, et\u00a0al. Utility of transperineal and anal ultrasonography in the diagnostics of hidradenitis suppurativa and its differentiation from a rectal fistula. Postepy Hig Med Dosw (Online). 2012;66:838\u201342.","journal-title":"Postepy Hig Med Dosw (Online)"},{"issue":"4","key":"1457_CR48","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1097\/MPG.0000000000000185","volume":"60","author":"B Natarajan","year":"2015","unstructured":"Natarajan B, et\u00a0al. Hidradenitis suppurativa and pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2015;60(4):e29-30.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"1457_CR49","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1097\/MPG.0b013e3182474d78","volume":"56","author":"S Sava\u015fan","year":"2013","unstructured":"Sava\u015fan S, El-Baba M. First episode of axillary acne inversa in a teenager on infliximab therapy for Crohn disease. J Pediatr Gastroenterol Nutr. 2013;56(1):e2-3.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"4","key":"1457_CR50","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1001\/jamadermatol.2015.6264","volume":"152","author":"A Egeberg","year":"2016","unstructured":"Egeberg A, Gislason GH, Hansen PR. Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa. JAMA Dermatol. 2016;152(4):429\u201334.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1457_CR51","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jaad.2016.03.025","volume":"75","author":"MA Gonz\u00e1lez-L\u00f3pez","year":"2016","unstructured":"Gonz\u00e1lez-L\u00f3pez MA, et\u00a0al. Increased prevalence of subclinical atherosclerosis in patients with hidradenitis suppurativa (HS). J Am Acad Dermatol. 2016;75(2):329\u201335.","journal-title":"J Am Acad Dermatol"},{"key":"1457_CR52","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.atherosclerosis.2017.10.001","volume":"267","author":"V De Vita","year":"2017","unstructured":"De Vita V, Hansen PR. Interleukin-32 may contribute to increased risk of cardiovascular disease in patients with hidradenitis suppurativa. Atherosclerosis. 2017;267:175.","journal-title":"Atherosclerosis"},{"issue":"2","key":"1457_CR53","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/bjd.13777","volume":"173","author":"G Shalom","year":"2015","unstructured":"Shalom G, et\u00a0al. Hidradenitis suppurativa and metabolic syndrome: a comparative cross-sectional study of 3207 patients. Br J Dermatol. 2015;173(2):464\u201370.","journal-title":"Br J Dermatol"},{"issue":"7","key":"1457_CR54","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1111\/jdv.14076","volume":"31","author":"JC Pascual","year":"2017","unstructured":"Pascual JC, et\u00a0al. Assessment of subclinical atherosclerosis in hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2017;31(7):1229\u201338.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1457_CR55","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.clindermatol.2017.09.007","volume":"36","author":"T Ergun","year":"2018","unstructured":"Ergun T. Hidradenitis suppurativa and the metabolic syndrome. Clin Dermatol. 2018;36(1):41\u20137.","journal-title":"Clin Dermatol"},{"issue":"1","key":"1457_CR56","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2018.02.050","volume":"79","author":"JJ Wu","year":"2018","unstructured":"Wu JJ, et\u00a0al. The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-\u03b1 inhibitors versus phototherapy: an observational cohort study. J Am Acad Dermatol. 2018;79(1):60\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1457_CR57","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jaad.2016.07.042","volume":"76","author":"JJ Wu","year":"2017","unstructured":"Wu JJ, et\u00a0al. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-\u03b1 inhibitors versus methotrexate. J Am Acad Dermatol. 2017;76(1):81\u201390.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1457_CR58","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/ced\/llae324","volume":"50","author":"N Kearney","year":"2025","unstructured":"Kearney N, et\u00a0al. Treatment of hidradenitis suppurativa with adalimumab in the PIONEER I and II randomized controlled trials reduced indices of systemic inflammation, recognized risk factors for cardiovascular disease. Clin Exp Dermatol. 2025;50(2):339\u201347.","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"1457_CR59","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1111\/bjd.14024","volume":"173","author":"T Tzellos","year":"2015","unstructured":"Tzellos T, et\u00a0al. Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies. Br J Dermatol. 2015;173(5):1142\u201355.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1457_CR60","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1111\/bjd.14170","volume":"173","author":"RC Simpson","year":"2015","unstructured":"Simpson RC. Cardiovascular disease risk factors in patients with hidradenitis suppurativa. Br J Dermatol. 2015;173(5):1118\u20139.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1457_CR61","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/bjd.15770","volume":"178","author":"A Garg","year":"2018","unstructured":"Garg A, et\u00a0al. Prevalence of hidradenitis suppurativa among patients with Down syndrome: a population-based cross-sectional analysis. Br J Dermatol. 2018;178(3):697\u2013703.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1457_CR62","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2340\/00015555-3095","volume":"99","author":"F Poizeau","year":"2019","unstructured":"Poizeau F, et\u00a0al. Prevalence and description of hidradenitis suppurativa in down syndrome: a cross-sectional study of 783 subjects. Acta Derm Venereol. 2019;99(3):351\u20132.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"1457_CR63","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/bjd\/ljad108","volume":"189","author":"A Sokoloff","year":"2023","unstructured":"Sokoloff A, et\u00a0al. If my hidradenitis had a voice, this is what it would say: the perspective of a young woman with Down syndrome and hidradenitis suppurativa. Br J Dermatol. 2023;189(2):221\u20132.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1457_CR64","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/pde.14326","volume":"37","author":"M Lam","year":"2020","unstructured":"Lam M, et\u00a0al. Hidradenitis suppurativa and Down syndrome: a systematic review and meta-analysis. Pediatr Dermatol. 2020;37(6):1044\u201350.","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"1457_CR65","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/pde.14214","volume":"37","author":"JF Rork","year":"2020","unstructured":"Rork JF, et\u00a0al. Dermatologic conditions in Down syndrome: a single-center retrospective chart review. Pediatr Dermatol. 2020;37(5):811\u20136.","journal-title":"Pediatr Dermatol"},{"issue":"8","key":"1457_CR66","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1111\/ijd.17261","volume":"63","author":"DD Dao","year":"2024","unstructured":"Dao DD, et\u00a0al. Demographics and treatment trends in the largest cohort of patients with Down syndrome and hidradenitis suppurativa. Int J Dermatol. 2024;63(8):e180\u20131.","journal-title":"Int J Dermatol"},{"issue":"6","key":"1457_CR67","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1111\/bjd.12887","volume":"170","author":"J Blok","year":"2014","unstructured":"Blok J, Jonkman M, Horv\u00e1th B. The possible association of hidradenitis suppurativa and Down syndrome: is increased amyloid precursor protein expression resulting in impaired Notch signalling the missing link? Br J Dermatol. 2014;170(6):1375\u20137.","journal-title":"Br J Dermatol"},{"issue":"1\u20132","key":"1457_CR68","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000487799","volume":"234","author":"G Giovanardi","year":"2018","unstructured":"Giovanardi G, et\u00a0al. Hidradenitis suppurativa associated with down syndrome is characterized by early age at diagnosis. Dermatology. 2018;234(1\u20132):66\u201370.","journal-title":"Dermatology"},{"issue":"2","key":"1457_CR69","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.det.2023.12.004","volume":"42","author":"CA Maronese","year":"2024","unstructured":"Maronese CA, Moltrasio C, Marzano AV. Hidradenitis suppurativa-related autoinflammatory syndromes: an updated review on the clinics, genetics, and treatment of pyoderma gangrenosum, acne and suppurative hidradenitis (PASH), pyogenic arthritis, pyoderma gangrenosum, acne and suppurative hidradenitis (PAPASH), synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO), and rarer forms. Dermatol Clin. 2024;42(2):247\u201365.","journal-title":"Dermatol Clin"},{"issue":"5","key":"1457_CR70","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1159\/000521263","volume":"238","author":"AV Marzano","year":"2022","unstructured":"Marzano AV, et\u00a0al. Whole-exome sequencing in 10 unrelated patients with syndromic hidradenitis suppurativa: a preliminary step for a genotype-phenotype correlation. Dermatology. 2022;238(5):860\u20139.","journal-title":"Dermatology"},{"issue":"11","key":"1457_CR71","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1001\/archdermatol.2010.328","volume":"146","author":"JL Hsiao","year":"2010","unstructured":"Hsiao JL, et\u00a0al. Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review. Arch Dermatol. 2010;146(11):1265\u201370.","journal-title":"Arch Dermatol"},{"issue":"2","key":"1457_CR72","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/1346-8138.17031","volume":"51","author":"K Yamanaka","year":"2024","unstructured":"Yamanaka K. New treatment of pyoderma gangrenosum and hidradenitis suppurativa: a review. J Dermatol. 2024;51(2):172\u20139.","journal-title":"J Dermatol"},{"issue":"8","key":"1457_CR73","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/ijd.13603","volume":"56","author":"C Vinkel","year":"2017","unstructured":"Vinkel C, Thomsen SF. Autoinflammatory syndromes associated with hidradenitis suppurativa and\/or acne. Int J Dermatol. 2017;56(8):811\u20138.","journal-title":"Int J Dermatol"},{"issue":"3","key":"1457_CR74","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/wrr.13016","volume":"30","author":"J Kim","year":"2022","unstructured":"Kim J. Uncovering a prominent association between pyoderma gangrenosum and hidradenitis suppurativa. Wound Repair Regen. 2022;30(3):297\u20138.","journal-title":"Wound Repair Regen"},{"issue":"11","key":"1457_CR75","doi-asserted-by":"publisher","first-page":"e585","DOI":"10.1111\/ijd.16766","volume":"62","author":"DA Marletta","year":"2023","unstructured":"Marletta DA, et\u00a0al. A case of PASH syndrome treated with guselkumab. Int J Dermatol. 2023;62(11):e585\u20137.","journal-title":"Int J Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01457-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01457-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01457-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T22:57:10Z","timestamp":1757199430000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01457-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":75,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1457"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01457-4","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"assertion":[{"value":"12 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Teja Mallela, Luke Passannante, Hiral Patel, and Leslie Onyeji report no disclosures. Dr. Christopher Sayed reports being an investigator for AbbVie, Astrazeneca, ChemoCentryx, Incyte, InflaRx, Novartis, and UCB Pharma; receiving consultancy fees from AbbVie, Lumis, Astrazeneca, InflaRx, Sandoz, Incyte, Logical Images, Sanofi, Moonlake Therapeutics, Sonoma Biotherapeutics, and UCB Pharma; and being a speaker for AbbVie and Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}